leukotriene receptor antagonist

出典: meddic

leukotriene antagonist

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/04/04 22:41:47」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria.
  • Wan KS1, Chang YS.Author information 1Department of Pediatrics, Taipei City Hospital , Renai Branch , Taiwan and.AbstractBACKGROUND: The efficacy of the combination of leukotriene receptor antagonist (LRA) and H1 antihistamine was similar to the synergistic regimen of H1 and H2 antihistamine for treatment of chronic idiopathic urticaria (CIU). However, the effective rates of these two regimens were only 53.3% and 63.3%, respectively.
  • The Journal of dermatological treatment.J Dermatolog Treat.2014 Dec;25(6):459-61. doi: 10.3109/09546634.2013.849791. Epub 2013 Nov 5.
  • BACKGROUND: The efficacy of the combination of leukotriene receptor antagonist (LRA) and H1 antihistamine was similar to the synergistic regimen of H1 and H2 antihistamine for treatment of chronic idiopathic urticaria (CIU). However, the effective rates of these two regimens were only 53.3% and 63.3
  • PMID 24192062
  • Protective effect of pranlukast on Aβ 1-42-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1.
  • Tang SS1, Ji MJ1, Chen L1, Hu M1, Long Y1, Li YQ1, Miao MX1, Li JC1, Li N2, Ji H1, Chen XJ2, Hong H1.Author information 1Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China.2Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.AbstractDeposition of extracellular amyloid-β (Aβ) peptide is one of the pathological hallmarks of Alzheimer's disease (AD). Accumulation of Aβ is thought to associate with cognition deficits, neuroinflammation and apoptosis observed in AD. However, effective neuroprotective approaches against Aβ neurotoxicity are unavailable. In the present study, we analysed the effects of pranlukast, a selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, on the impairment of learning and memory formation induced by Aβ and the probable underlying electrophysiological and molecular mechanisms. We found that bilateral intrahippocampal injection of Aβ 1-42 resulted in a significant decline of spatial learning and memory of mice in the Morris water maze (MWM) and Y-maze tests, together with a serious depression of in vivo hippocampal long-term potentiation (LTP) in the CA1 region of the mice. Importantly, this treatment caused significant increases in CysLT1R expression and subsequent NF-κB signaling, caspase-3 activation and Bcl-2 downregulation in the hippocampus or prefrontal cortex. Oral administration of pranlukast at 0.4 or 0.8 mg/kg for 4 wk significantly reversed Aβ 1-42-induced impairments of cognitive function and hippocampal LTP in mice. Furthermore, pranlukast reversed Aβ 1-42-induced CysLT1R upregulation, and markedly suppressed the Aβ 1-42-triggered NF-κB pathway, caspase-3 activation and Bcl-2 downregulation in the hippocampus and prefrontal cortex in mice. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay confirmed its presence in the brain after oral administration of pranlukast in mice. These data disclose novel findings about the therapeutic potential of pranlukast, revealing a previously unknown therapeutic possibility to treat memory deficits associated with AD.
  • The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP).Int J Neuropsychopharmacol.2014 Apr;17(4):581-92. doi: 10.1017/S1461145713001314. Epub 2013 Nov 11.
  • Deposition of extracellular amyloid-β (Aβ) peptide is one of the pathological hallmarks of Alzheimer's disease (AD). Accumulation of Aβ is thought to associate with cognition deficits, neuroinflammation and apoptosis observed in AD. However, effective neuroprotective approaches against Aβ neurot
  • PMID 24229499
  • Effectiveness of the leukotriene receptor antagonist pranlukast hydrate for the treatment of sleep disorder in patients with perennial allergic rhinitis.
  • Hara H1, Sugahara K, Hashimoto M, Mikuriya T, Tahara S, Yamashita H.Author information 1Department of Otolaryngology, Yamaguchi University Graduate School of Medicine , Ube, Yamaguchi , Japan.AbstractAbstract Conclusion: We found that addition of pranlukast to the conventional treatment for perennial allergic rhinitis may contribute to improvements in sleep disorder symptoms through a decrease in nasal congestion. Objective: We aimed to determine whether the leukotriene receptor antagonist pranlukast hydrate is effective in treating sleep disorder in patients with perennial allergic rhinitis. Methods: We conducted a questionnaire survey to determine the symptoms of rhinitis and sleep disturbances in 48 adult patients with perennial allergic rhinitis who visited the outpatient otolaryngology departments in hospitals in Yamaguchi Prefecture, Japan. The subjects presented with nasal symptoms and symptoms of sleep disorder during the last 2 weeks of treatment for allergic rhinitis that lasted for at least 1 month. A questionnaire based on the Pittsburgh Sleep Quality Index and Athens Insomnia Scale with some modifications was administered before and 4 weeks after the addition of pranlukast to the conventional treatment. Results: Addition of pranlukast improved the symptoms of perennial allergic rhinitis, with responses to all items of the questionnaire administered 4 weeks after pranlukast addition indicating significant improvements. Furthermore, the improvement in sleep disorder symptoms significantly correlated with improvement in nasal congestion, but not with improvements in sneezing and nasal discharge.
  • Acta oto-laryngologica.Acta Otolaryngol.2014 Mar;134(3):307-13. doi: 10.3109/00016489.2013.861926. Epub 2014 Jan 27.
  • Abstract Conclusion: We found that addition of pranlukast to the conventional treatment for perennial allergic rhinitis may contribute to improvements in sleep disorder symptoms through a decrease in nasal congestion. Objective: We aimed to determine whether the leukotriene receptor antagonist pranl
  • PMID 24460152

和文文献

  • 東京都における遷延性・慢性咳嗽および咳喘息の診療実態調査
  • 切士 紗織,原 香織,久保 綾子 [他]
  • アレルギー・免疫 21(12), 1942-1949, 2014-12
  • NAID 40020269765
  • Cysteinyl leukotriene receptor antagonist regulates allergic airway inflammation in an organ- and cytokine-specific manner
  • Kawano Tetsuya,Matsuse Hiroto,Tsuchida Tomoko,Fukahori Susumu,Fukushima Chizu,Nishino Tomoya,Kohno Shigeru
  • Medical Science Monitor 20, 297-302, 2014-02-22
  • … Cys-LT receptor antagonists (LTRAs) decrease allergic airway inflammation. …
  • NAID 120005438870
  • 救急病院における喘息患者の治療実態アンケート : 兵庫県喘息死ゼロ作戦活動報告
  • 堀 朱矢,西村 善博,新家 治子,櫨木 暢子,小林 和幸,片山 覚
  • アレルギー 63(1), 52-60, 2014-02-01
  • 【目的】救急現場の喘息治療の実態を把握することを目的とした.【方法】2010年4月から1年間の救急診療状況について,兵庫県下の2次・3次救急を扱う175医療機関に対しアンケート調査を実施し, 2次医療圏ごとに検討した.【結果】143医療機関(回答率81.7%)から回答を得た.救急処置室での治療薬としては,ステロイド注射薬やアミノフィリン注射用製剤,SABAが多くの地区で選択されていた(順に平均86 …
  • NAID 110009798513

関連リンク

Definition of leukotriene receptor antagonist in the Medical Dictionary. leukotriene receptor antagonist explanation. Information about leukotriene receptor antagonist in Free online English dictionary. What is leukotriene receptor ...
This page includes the following topics and synonyms: Leukotriene Receptor Antagonist, Leukotriene Synthesis Inhibitor, Accolate, Zafirlukast, Montelukast, Singulair, Zileuton, Zyflo. ... Definition (NCI) The active ingredient in a drug ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元ロイコトリエン受容体拮抗薬」「ロイコトリエン受容体遮断薬」「LTRA」「leukotriene antagonist
拡張検索leukotriene receptor antagonists
関連記事antagonist」「receptor」「leukotriene receptor」「leukotriene」「leukotrienes

ロイコトリエン受容体拮抗薬」

  [★]

leukotriene receptor antagonist, LTRA
ロイコトリエン拮抗薬ロイコトリエン受容体遮断薬抗SRS-A剤
[show details]



ロイコトリエン受容体遮断薬」

  [★]

leukotriene receptor antagonist
ロイコトリエン受容体拮抗薬


LTRA」

  [★] ロイコトリエン受容体拮抗薬 leukotriene receptor antagonist


leukotriene antagonist」

  [★]

leukotriene receptor antagonist


leukotriene receptor antagonists」

  [★] ロイコトリエン受容体拮抗薬 LTRAs


antagonist」

  [★] 拮抗薬

WordNet   license wordnet

「a drug that neutralizes or counteracts the effects of another drug」

WordNet   license wordnet

「a muscle that relaxes while another contracts; "when bending the elbow the triceps are the antagonist"」

PrepTutorEJDIC   license prepejdic

「対立する人,敵対者,競争相手(opponent)」


receptor」

  [★] 受容体

WordNet   license wordnet

「a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response」

PrepTutorEJDIC   license prepejdic

「=sense organ / 受信装置」


leukotriene receptor」

  [★]


leukotriene」

  [★] ロイコトリエン LT


leukotrienes」

  [★] ロイコトリエン LT




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡